-transparent.png){kind=logo}
In the last decade large amounts of intravenous immunoglobulin (i.v.Ig) have been used worldwide. Doubts exist as to whether this increased use is paralleled by a comparable growth of reliable data on the therapeutic effectiveness of i.v.Ig. We performed a literature search using MEDLINE from January 1981 to January 1997 and analysed articles on the use of i.v.Ig in hematological disorders and searched for published guidelines. For most hematological disorders, evidence to use i.v.Ig as first line therapy is not very strong. For many disorders no controlled trials have been performed. In published guidelines, i.v.Ig is only recommended, with a few exceptions, when other treatments have failed or are contraindicated. Therefore the increase of consumption of i.v.Ig can not be explained by an increase in established indications in hematology.
A Otten, and
P M Bossuyt, and
M Vermeulen, and
A Brand
June 2007,
Recenti progressi in medicina,
A Otten, and
P M Bossuyt, and
M Vermeulen, and
A Brand
January 1998,
Journal of the neurological sciences,
A Otten, and
P M Bossuyt, and
M Vermeulen, and
A Brand
January 2017,
Pediatric annals,
A Otten, and
P M Bossuyt, and
M Vermeulen, and
A Brand
July 1992,
The American journal of medicine,
A Otten, and
P M Bossuyt, and
M Vermeulen, and
A Brand
April 2021,
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,
A Otten, and
P M Bossuyt, and
M Vermeulen, and
A Brand
January 2015,
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova,
A Otten, and
P M Bossuyt, and
M Vermeulen, and
A Brand
June 2011,
Nature reviews. Rheumatology,
A Otten, and
P M Bossuyt, and
M Vermeulen, and
A Brand
May 2004,
JAMA,
A Otten, and
P M Bossuyt, and
M Vermeulen, and
A Brand
April 2013,
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
A Otten, and
P M Bossuyt, and
M Vermeulen, and
A Brand
January 1993,
Clinical and experimental rheumatology,
